{"id":395,"date":"2020-07-25T08:37:27","date_gmt":"2020-07-25T08:37:27","guid":{"rendered":"https:\/\/nclinnovations.org\/covid19monitor\/?p=395"},"modified":"2020-07-25T08:37:27","modified_gmt":"2020-07-25T08:37:27","slug":"24-july-2020-hydroxychloroquine-data-from-prevention-and-early-treatment-trials-did-not-suggest-significant-safety-concerns","status":"publish","type":"post","link":"https:\/\/nclinnovations.org\/covid19monitor\/24-july-2020-hydroxychloroquine-data-from-prevention-and-early-treatment-trials-did-not-suggest-significant-safety-concerns\/","title":{"rendered":"(24 July 2020)- Hydroxychloroquine- data from prevention and early treatment trials did not suggest significant safety concerns"},"content":{"rendered":"<div class=\"boldgrid-section\">\n<div class=\"container\">\n<div class=\"row\">\n<div class=\"col-md-12 col-xs-12 col-sm-12\">\n<p class=\"\">Safety of Hydroxychloroquine among Outpatient Clinical Trial Participants for COVID-19<\/p>\n<p>https:\/\/doi.org\/10.1101\/2020.07.16.20155531.this<\/p>\n<p class=\"\">Results from&nbsp; three randomized, double-blind, placebo-controlled trials (NCT04308668, NCT04308668) investigating hydroxychloroquine as pre-exposure prophylaxis, post-exposure prophylaxis and early treatment for COVID-19 are presented.&nbsp; 2,795 participants were enrolled. Overall 2,324 (84%) participants reported side effect data, and 638 (27%) reported at least one medication side effect. Side effects were reported in 29% with daily, 36% with twice weekly, 31% with once weekly hydroxychloroquine compared to 19% with placebo. The most common side effects were upset stomach or nausea (25% with daily, 18% with twice weekly, 16% with weekly, vs. 10% for placebo), followed by diarrhea, vomiting, or abdominal pain (23% for daily, 16% twice weekly, 12% weekly, vs. 6% for placebo). Two individuals were hospitalized for atrial arrhythmias, one on placebo and one on twice weekly hydroxychloroquine. No sudden deaths occurred. Data from three outpatient COVID-19 trials demonstrated that gastrointestinal side effects were common but mild with the use of hydroxychloroquine, while serious side effects were rare. No deaths occurred related to hydroxychloroquine.&nbsp;<\/p>\n<\/div>\n<\/div>\n<\/div>\n<\/div>\n","protected":false},"excerpt":{"rendered":"<p>Safety of Hydroxychloroquine among Outpatient Clinical Trial Participants for COVID-19 https:\/\/doi.org\/10.1101\/2020.07.16.20155531.this Results from&nbsp; three randomized, double-blind, placebo-controlled trials (NCT04308668, NCT04308668) investigating hydroxychloroquine as pre-exposure prophylaxis, post-exposure prophylaxis and early treatment for COVID-19 are presented.&nbsp; 2,795 participants were enrolled. Overall 2,324&hellip; <span class=\"read-more-span\"><a href=\"https:\/\/nclinnovations.org\/covid19monitor\/24-july-2020-hydroxychloroquine-data-from-prevention-and-early-treatment-trials-did-not-suggest-significant-safety-concerns\/\" class=\"more-link\">Continue reading<span class=\"screen-reader-text\"> &#8220;(24 July 2020)- Hydroxychloroquine- data from prevention and early treatment trials did not suggest significant safety concerns&#8221;<\/span> <span class=\"genericon genericon-next\"><\/span><\/a><\/span><\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"bgseo_title":"","bgseo_description":"","bgseo_robots_index":"index","bgseo_robots_follow":"follow"},"categories":[4,9],"tags":[10],"_links":{"self":[{"href":"https:\/\/nclinnovations.org\/covid19monitor\/wp-json\/wp\/v2\/posts\/395"}],"collection":[{"href":"https:\/\/nclinnovations.org\/covid19monitor\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/nclinnovations.org\/covid19monitor\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/nclinnovations.org\/covid19monitor\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/nclinnovations.org\/covid19monitor\/wp-json\/wp\/v2\/comments?post=395"}],"version-history":[{"count":1,"href":"https:\/\/nclinnovations.org\/covid19monitor\/wp-json\/wp\/v2\/posts\/395\/revisions"}],"predecessor-version":[{"id":396,"href":"https:\/\/nclinnovations.org\/covid19monitor\/wp-json\/wp\/v2\/posts\/395\/revisions\/396"}],"wp:attachment":[{"href":"https:\/\/nclinnovations.org\/covid19monitor\/wp-json\/wp\/v2\/media?parent=395"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/nclinnovations.org\/covid19monitor\/wp-json\/wp\/v2\/categories?post=395"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/nclinnovations.org\/covid19monitor\/wp-json\/wp\/v2\/tags?post=395"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}